ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) shares jumped above 14% in the last trading session.
ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.
ImmunoGen (IMGN) Reports Narrower-than-Expected Loss
by Zacks Equity Research
ImmunoGen posted narrower-than-expected loss in the first quarter of 2017.
What's in the Cards for Allergan (AGN) this Earnings Season?
by Zacks Equity Research
Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.
Why ImmunoGen (IMGN) Might Surprise This Earnings Season
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and ImmunoGen, Inc. (IMGN) may be one such company.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter.
Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?
by Zacks Equity Research
Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens.
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.
Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) is scheduled to report first-quarter 2017 results on May 5, before the opening bell.
Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
We expect Conatus Pharmaceuticals Inc. (CNAT) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
ImmunoGen (IMGN) Up 47.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.
ImmunoGen (IMGN) Reports Wider-than-Expected Loss
by Zacks Equity Research
ImmunoGen posted marginally wider-than-expected loss in the quarter (ending Dec 31, 2016). Our consensus called for a loss of 38 cents per share, and the company reported a loss of 39 cents per share (excluding restructuring charge).
What's in Store for ImmunoGen (IMGN) this Earnings Season?
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.
Immunogen Doses First Patient in Ovarian Cancer Drug Study
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) announced that the first patient has been dosed in FORWARD I, the company's phase III study, assessing mirvetuximab soravtansine, as a single-agent therapy for the treatment of platinum-resistant ovarian cancer.
ImmunoGen: Phase I Data on Ovarian Cancer Drug Published
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.
Big Changes to BioShares Biotech ETFs: Who's In, Who's Out?
by Sanghamitra Saha
Inside the changes in portfolio constituents of two BioShares Biotech ETFs.